The CD86 occupancy assay has been developed to measure the number of CD86 molecules unbound to belatacept, but its association with clinical outcomes has not been assessed yet. All kidney transplant patients switched to belatacept in our center between 2016 and 2018 were included. Blood samples were collected before each infusion for 1 year to assess CD86 occupancy by CD86 antibody cytometry staining on the surface of CD14 monocytes. Results were expressed as the median fluorescence intensity (MFI) value of CD86 staining. At each infusion, the MFI /MFI ratio was calculated. Forty-one patients were consecutively included. After every 2-week infusion period, CD86 MFI ratio dropped from 1.00 to 0.73 [0.57-0.98], p = .07. However, this ratio progressively increased to 0.78 [0.53-1.13] at 1 year, which was not statistically different from pre-switch ratio, p = .4. Over the first year, the MFI ratio coefficient of variation was 31.58% [23.75-38.31]. MFI ratio was not different between patients with or without opportunistic infections: 0.73 [0.60-0.88] versus 0.80 [0.71-1.00], p = .2, or between patients with or without EBV DNAemia, p = .2. Despite previous in vitro results, the CD86 occupancy assay suffers from a high intra-individual variability and does not appear to be relevant to clinical outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajt.17005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.
Cancer Discov
May 2023
Sorbonne Université, INSERM, Department of Internal Medicine, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
Article Synopsis
- The study investigates the connection between immune-checkpoint inhibitor (ICI)-associated myotoxicity, specifically looking at myocarditis and myositis, which can be life-threatening.
- It details a treatment strategy that involved the use of mechanical ventilation for respiratory muscle issues and the administration of the drugs abatacept and ruxolitinib in patients diagnosed with severe ICI myocarditis.
- Results showed a significant drop in myotoxicity-related fatalities from 60% in the initial patient group to just 3.4% in the later group, indicating the effectiveness of early intervention and specific treatment adjustments.
Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept.
J Immunother Cancer
April 2022
Department of Pharmacology, UNICO-GRECO Cardio-Oncology Program, Sorbonne Université, INSERM CIC-1901, AP.HP.Sorbonne, Pitié-Salpêtrière Hospital, Paris, France
Immune-checkpoint inhibitors (ICI) have revolutionized cancer therapy but are associated with infrequent but lethal myocarditis, for which management remains uncertain. Abatacept, a CTLA-4 fusion protein targeting CD86 on antigen presenting cells and leading to global T-cell anergy, has been described as a potential treatment in individual reports. Yet, abatacept treatment dosage, schedule and optimal combination with other immunosuppressive therapies are unclear.
View Article and Find Full Text PDFCD86 occupancy in belatacept-treated kidney transplant patients is not associated with clinical and infectious outcomes.
Am J Transplant
June 2022
Nephrology - Kidney Transplant Unit, Rouen University Hospital, Rouen, France.
The CD86 occupancy assay has been developed to measure the number of CD86 molecules unbound to belatacept, but its association with clinical outcomes has not been assessed yet. All kidney transplant patients switched to belatacept in our center between 2016 and 2018 were included. Blood samples were collected before each infusion for 1 year to assess CD86 occupancy by CD86 antibody cytometry staining on the surface of CD14 monocytes.
View Article and Find Full Text PDFBlocking T cell co-stimulation in primary Sjögren's syndrome: rationale, clinical efficacy and modulation of peripheral and salivary gland biomarkers.
Clin Exp Rheumatol
October 2020
Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK.
There is accumulating evidence that patients with primary Sjögren's syndrome (pSS) display aberrant CD4+ T cell responses, both in the peripheral compartment and in the inflamed salivary glands. CD4+ T cell abnormalities are also critically associated with B cell hyper activation, one of the hallmarks of disease, which is linked with disease severity and evolution to lymphoma. T cell activation and the cross-talk between T and B cells are tightly regulated by the balance between co-stimulatory pathways, such as the interactions between CD80/CD86:CD28, CD40:CD40L and ICOS:ICOSL, and co-inhibitory signals, including the immunoregulatory CTLA-4 protein.
View Article and Find Full Text PDFPhase I study of single-dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients.
Am J Transplant
April 2019
Department of Pediatrics, UCLA Mattel Children's Hospital, Los Angeles, California.
Belatacept is an intravenously infused selective T cell costimulation blocker approved for preventing organ rejection in renal transplant recipients aged ≥18 years. This phase I trial examined the pharmacokinetics and pharmacodynamics (percentage CD86 receptor occupancy [%CD86RO]) of a single dose of belatacept (7.5 mg/kg) administered to kidney transplant recipients aged 12-17 years receiving a stable calcineurin inhibitor-based immunosuppressive regimen.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!